VacZine Analytics - company overview 2017

Cat No: VADIP001 © VacZine Analytics 2017VacZine Analytics and the “spiral” logo are UK registered trademarks

Company Overview

For the year 2017

@vaczineanalytic

Contents

1. What is VacZine Analytics?

2. What is our mission?

3. We support a growing industry

4. Many global pathogens still without a vaccine, but progress!

5. What client activities do we support?

6. Techniques/capabilities

7. Methodology and process

8. What is MarketVIEW?

9. Our Product Portfolio: 2010-2017

10. Our clients

11. How we compare

© VacZine Analytics 2017. All rights reserved.© VacZine Analytics and the “spiral” logo are UK Registered Trademarks.

2

What is VacZine Analytics?

VacZine Analytics (VA) is an established strategic research consultancy/publisher formed in the United Kingdom

• The company is investor backed and has traded profitably since September 2007

VA was formed to meet growing demand for high-quality vaccine commercial analysis/market information

VA consists of a “trusted” network of consultants mainly ex-vaccines/pharma/agency

VA currently trades with most major vaccine companies

© VacZine Analytics 2017. All rights reserved.

3

What is our mission?

1. To enable vaccine clients to make better-informed business decisions

2. To help clients build the case for developing new vaccines

3. To foster the free-flow of vaccine related information


4

We support a growing industry


5

Sa

les

($ 0

00

s)

Year

Note: Top 5 companies only – after December 2016, Sanofi will consolidate SPMSD sales (50/50 joint venture with SP and Merck & Co)Other companies estimated to be 15% of total vaccine market – not included in total.*Novartis (Chiron) sales does not include diagnostics division, now sold to GSK Biologicals and CSL (Seqirus)Where companies report in €, conversions are made using average $ exchange for year

0

5,000

10,000

15,000

20,000

25,000

2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

Seqirus

Novartis Vaccines*

Sanofi Pasteur

Pfizer (Wyeth)

Merck & Co

GSK Biologicals

CAGR 2003-16 ~11%


6

Many global pathogens still without a vaccine, but progress!

Note: Hepatitis E vaccine now approved in China (Hecolin)

New vaccines

What client activities do we support?

Disease analysis• Identification of key trends, issues and dynamics

Building new business• New product strategy/R&D prioritization

Growing existing business

• Lifecycle management opportunities

Finding new business• Commercial due diligence/horizon scanning

Planning the future• Strategic planning/internal consultation


7

What techniques do we use?

Our products/services are produced using rigorous techniques of:

Desk-based research & analysis

Opinion leader consultation (growing panel of >50 experts)

Forecasting and modeling

Expert synthesis and conceptualization

Our personnel have:

>10 yrs experience

Are based in US/EU

Conduct all Western market interviews/analysis “in house”

Have extensive global partners e.g. presence in emerging nations


8

Our research products are produced only in the United Kingdom or United States

Methodology and process

9

75 syndicated products now available!

MarketVIEW is a vaccine commercial opportunity assessment. It is composed of a detailed MS Excel workbook(s) (.xls) and Executive presentation (.pdf)

MarketVIEW is designed to give you the most essential readouts for the vaccine market you are evaluating. For new vaccine products it will provide (not limited to):

Disease background and epidemiologyCurrent management and treatmentUnmet needsNeed and rationale for vaccineTarget product profile(s)Predicted launch date(s) per region/countryProduct volume estimates (mio doses)Pricing considerationsGross sales revenue estimatesMarket share estimatesSales revenue per segment/region estimatesLatest competitive dynamicsR&D pipeline


10

DOWNLOAD BROCHURE AT: http://www.vaczine-analytics.com/products-marketview.asp

What is MarketVIEW?

Note: typical countries covered are the seven major markets although this may vary

Our Product Portfolio: 2017-2010

The most comprehensive and up-to-date range of vaccine related commercial analyses in the industry

75 products now available!

*Executive presentation OR Model**Executive presentation PLUS Model © VacZine Analytics 2017. All rights reserved.

For further information, to place an order or request a proposal please contact [email protected]

Continued ..

Cat No. Report TitlePublication

Date

Single*

(USD $)

Full**

(USD $)

VAMV025a MarketVIEW: Dengue travel vaccines Jul '17 6,996.50 9,995.00

VAMV066 MarketVIEW: Rhinovirus May '17 7,996.50 10,995.00

VAMV070 MarketVIEW: Acinetobacter baumannii Apr '17 7,695.00 10,995.00

VAMV016 MarketVIEW: Herpes Simplex Virus vaccines (prophylatic) Mar '17 7,695.00 10,995.00

VAMV025 MarketVIEW: Dengue endemic vaccines Feb '17 7,695.00 10,995.00

VAMV038 MarketVIEW: Herpes Simplex Virus vaccines (therapeutic) Feb '17 7,695.00 10,995.00

VAMV072 MarketVIEW: Therapeutic cancer vaccines overview Feb '17 7,695.00 -

VAMV011 MarketVIEW: Japanese encephalitis vaccines Jan '17 7,695.00 10,995.00

VAMV050 MarketVIEW: HPV therapeutic vaccines Dec '16 4,995.00 9,995.00

VAMV071 MarketVIEW: Campylobacter vaccines Nov '16 4,995.00 9,995.00

VAMV070 MarketVIEW: Acinetobacter baummannii Oct '16 4,995.00 9,995.00

VAMV069 MarketVIEW: Cholera vaccines Sept '16 4,995.00 9,995.00

VAMV020 MarketVIEW: Universal influenza vaccines Aug '16 4,995.00 9,995.00

VAMV036 MarketVIEW: Seasonal influenza vaccines May '16 4,995.00 9,995.00

VAMV023 MarketVIEW: Respiratory Syncytial virus vaccines Mar '16 4,995.00 9,995.00

VAMV068 MarketVIEW: Zika virus Feb '16 4,995.00 9,995.00

VAMV067 MarketVIEW: Shigellosis Jan '16 4,995.00 9,995.00

VAMV065 MarketVIEW: H.pylori Dec'15 4,995.00 9,995.00

VAMV064 MarketVIEW: Enteropathogenic E.coli Nov'15 4,995.00 9,995.00

VAMV015 MarketVIEW: Norovirus vaccines Oct' 15 4,995.00 9,995.00

VAMV063 MarketVIEW: Biodefense vaccines Sept '15 4,995.00 -

VAMV056 MarketVIEW: Epstein Barr Virus June '15 4,995.00 9,995.00

VAMV062 MarketVIEW: Human metapneumovirus May '15 4,995.00 9,995.00

VAMV061 MarketVIEW: Ebola vaccines April '15 4,995.00 9,995.00

VAMV033 MarketVIEW: Hepatitis B virus Mar '15 4,995.00 9,995.00

VAMV045 MarketVIEW: Cholesterol vaccines Feb '15 4,995.00 9,995.00

VAMV049 MarketVIEW: Parkinson disease vaccines Jan '15 4,995.00 9,995.00

VAMV060 MarketVIEW: Veterinary vaccine overview Nov '14 4,995.00 -

VAMV021 MarketVIEW: Tuberculosis vaccines Nov '14 4,995.00 9,995.00

VAMV054 MarketVIEW: Herpes zoster vaccines Oct '14 4,995.00 9,995.00

VAMV058 MarketVIEW: Measles, Mumps, Rubella vaccines Oct'14 4,995.00 9,995.00

VAMV014 MarketVIEW: Cytomegalovirus vaccines Aug '14 4,995.00 9,995.00

VAMV012 MarketVIEW: Allergic immunotherapies July '14 4,995.00 9,995.00

VAMV009 MarketVIEW: MenACWY vaccines July '14 4,995.00 9,995.00

VAMV057 MarketVIEW: Rotavirus vaccines June '14 4,995.00 9,995.00

VAMV005 MarketVIEW: Chikungunya vaccines June '14 3,995.00 7,995.00

VAMV008 MarketVIEW: Group B Streptococcus vaccines May '14 4,995.00 9,995.00

VAMV024 MarketVIEW: Lyme Borreliosis vaccines Apr '14 4,995.00 9,995.00

VAMV055 MarketVIEW: Rabies vaccines Mar '14 4,995.00 9,995.00

VAMV001 MarketVIEW: Clostridium difficile vaccines (West) Jan '14 4,995.00 9,995.00

11

Our Product Portfolio: 2017-2010 (cont..)

*Executive presentation OR Model**Executive presentation PLUS Model


For further information, to place an order or request a proposal please contact [email protected]

Cat No. Report TitlePublication

Date

Single*

(USD $)

Full**

(USD $)

VAMV051 MarketVIEW: Chagas disease vaccines Nov '13 1,662.74 3,325.48

VAMV053 MarketVIEW: Inactivated Polio vaccines Nov '13 1,847.57 3,695.14

VAMV050 MarketVIEW: HPV therapeutic vaccines Sept '13 1,847.57 3,695.14

VAMV047 MarketVIEW: Ross River Virus July '13 1,662.74 3,325.48

VAMV048 MarketVIEW: Cocaine dependance July' 13 1,662.74 3,325.48

VAMV019 MarketVIEW: Yellow Fever vaccines June '13 1,662.74 3,325.48

VAMV043 MarketVIEW: Diabetes vaccines June '13 1,662.74 3,325.48

VAMV046 MarketVIEW: Typhoid travel vaccines Apr '13 923.42 1,846.71

VAMV044 MarketVIEW: Smoking cessation vacccines Mar '13 1,662.74 3,325.48

VAMV025 MarketVIEW: Dengue vaccines Mar '13 2,032.52 4,064.92

VAMV042 MarketVIEW: Hepatitis C virus Feb '13 1,847.57 3,695.14

VAMV040 MarketVIEW: Hepatitis E virus Feb '13 1,662.74 3,325.48

VAMV041 MarketVIEW: Alzheimer's disease Jan '13 1,662.74 3,325.48

VAMV039 MarketVIEW: West Nile Virus Dec '12 1,247.08 2,494.17

VAMV029b MarketVIEW: Hepatitis A vaccines (travel) Oct '12 831.19 1,662.25

VAMV029c MarketVIEW: Hepatitis A vaccines (West) Oct '12 831.19 1,662.25

VAMV034 MarketVIEW: Acne vaccines Sept '12 1,247.08 2,494.17

VAMV029 MarketVIEW: Hepatitis A vaccines (Emerging/ROW) July '12 1,247.08 2,494.17

VAMV038 MarketVIEW: Herpes Simplex Virus vaccines (therapeutic) July '12 1,247.08 2,494.17

VAMV037 MarketVIEW: Candida vaccines July '12 1,108.49 2,216.86

VAMV003 MarketVIEW: Chlamydia trachomatis vaccines June '12 1,246.84 2,493.68

VAMV002 MarketVIEW: Staphylococcus aureus vaccines April '12 1,385.68 2,771.35

VAMV032 MarketVIEW: Enterovirus-71 vaccines Feb '12 1,385.68 2,771.35

VAMV031 MarketVIEW: Meningococcus serogroup B vaccines Jan '12 1,524.39 3,048.66

VAMV011 MarketVIEW: Japanese encephalitis vaccines Jan '12 1,247.08 2,494.17

VAMV030 MarketVIEW: Universal pneumo vaccines Jan '12 1,385.68 2,771.35

VAMV017 MarketVIEW: Malaria vaccines Nov '11 738.95 1,477.91

VAMV028 MarketVIEW: Travelers' diarrhea vaccines Oct '11 785.19 1,570.38

VAMV027 MarketVIEW: Group A Streptococcus vaccines June '11 831.43 1,662.74

VAMV026 MarketVIEW: Melanoma vaccines June '11 738.95 1,477.91

VAMV016 MarketVIEW: Herpes Simplex Virus vaccines (prophylatic) Feb '11 738.95 1,477.91

VAMV010 MarketVIEW: Pseudomonas aeruginosa vaccines Jan '11 738.95 1,477.91

VAMV022 MarketVIEW: Tick-borne Encephalitis vaccines Sept '10 369.54 738.95

VAMV018 MarketVIEW: Clostridium difficile vaccines (Emerging/ROW) Aug '10 461.89 923.78

The most comprehensive and up-to-date range of vaccine related commercial analyses in the industry

75 products now available!

12

Our clients


13

Compare our prices

14


Supplier Based in Productexample

Coverage Format Singleuser

Site license

Globallicense^

VacZine Analytics

United Kingdom MarketVIEW: Seasonal Influenza vaccines (Jun ‘16)

28 countries .pdf (122 slides)

.xls (120 worksheets)

n/a $10,995 $14,995

Globaldata1 United KingdomIndia*

PharmaPoint: Seasonal Influenza vaccines (Nov ‘16)

Seven major markets

.pdf (421 pages)KOLs

$10,995 $21,990 $32,985

Datamonitor2 United KingdomIndia*

Seasonal influenza vaccines(May ‘17)

Seven major markets

.pdf (134 pages)

£21,275

Renub Research3

India Global Influenza Vaccine Market &

Forecast (April ‘17)

30 countries .pdf (383 pages)

$2,985

1 – as listed on www.globaldata.com. Accessed September 2017. Other small product analyses are offered at different prices2 – as listed on https://pharmastore.informa.com/product/seasonal-influenza-vaccines/ Accessed September 2017. Other product analyses are offered at different prices3 – as listed on www.researchandmarkets.com Accessed September 2017

On line list price (single copy)

VacZine Analytics research reports are produced in the United Kingdom. They are composed of two detailed deliverables: an Executive Presentation (.pdf) and a MS-Excel forecast model (.xls). They are a full 10-15 year market forecast.

*have research operations in India, although reports maybe authored in the UK or US, ^sometimes referred to as ‘enterprise license’

Example

Compare our output & coverage

15


Supplier Product type 2017 2016 2015 2014 2013 All^

VacZine Analytics

MarketVIEW 10 9 10 16 12 78

Globaldata1 PharmaPoint 3 1 2 1

Datamonitor2 Market forecasts 1 2 2

1 – as listed on www.globaldata.com. Accessed September 20172 – as listed on https://pharmastore.informa.com/product/seasonal-influenza-vaccines/ Accessed September 20173 – as listed on www.researchandmarkets.com Accessed September 2017

Note: comparable products only to MarketVIEW. Competitors also produce smaller country based studies, KOL interviews and product monographs1. PharmaPoint: Seasonal Influenza (Nov ‘16), PharmaPoint: Meningococcal vaccines (May ’16), PharmaPoint: Hepatitis B vaccines (Jan ‘16), PharmaPoint:

Meningococcal vaccines (Nov ’15), PharmaPoint: Meningococcal vaccines (Mar’ ‘14) , PharmaPoint: Hepatitis B vaccines (Jan ‘14), PharmaPoint: Meningococcal vaccines (August ’13)

2. Seasonal Influenza Vaccines (May ‘17). Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2025 (June ‘16), Pneumococcal vaccines (August ‘17), Dengue vaccines (Sept ‘16)

No of market forecast reports released

^in whole portfolio

VacZine Analytics produces only full market forecast reports and releases on average ~10 studies per year in a wide range of infectious pathogens and chronic disorders. We believe our portfolio is the most comprehensive globally

Clostridium difficile - major interest area at formation


16

In 2007 we predicted the advent of preventative vaccines for healthcare-associated infections (HAIs)

This remains a strong research focus

VacZine Analytics: credible and cited source


» Sheridan C. Vaccine Market Boosters, Nature Biotechnology. June 2009, Volume 27 No 6 pp502-578

» Schomann-Finck C. Neue Euphorie. Money Maker. Focus Money Magazine (German), Issue 26, 2009

» Lucero CA., et al. Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population-based surveillance for invasive methicillin-resistant S. aureus disease in the United States. Vaccine. 2009 - In Press

17

About VacZine Analytics:

VacZine Analytics is an established research consultancy based in the United

Kingdom. Its aim is to provide high-quality disease and commercial analysis to those

working within or in collaboration with the vaccine industry.

With our product lines:

• MarketVIEW

• ExpertREACT

Our key focus is helping clients to build the case for developing new vaccines.


18

DisclaimerAll rights reserved

VacZine Analytics licensed products (or part thereof) may not be reproduced, stored in a retrieval systemor transmitted in any form without the written permission of the publisher VacZine Analytics (a division ofAssay Advantage Ltd).

The facts presented within this document, at the time of its production, were believed to be correct andwere gathered in good faith from both primary and secondary sources. VacZine Analytics is not always inthe position to assure that the facts are guaranteed. VacZine Analytics cannot be held liable for anyactions based upon facts or recommendations presented within this document.

VacZine Analytics operates according to Terms and Conditions of business which are available for viewAt: www.vaczine-analytics.com/legal-documents.asp

Assay Advantage (VacZine Analytics) is registered in England and Wales Company No: 5807728

19


20

Healthcare

VacZine Analytics - company overview 2017